Creating new antiviral medications for enterovirus infections
Official title: Development of 2C inhibitors as broad-spectrum enterovirus antivirals
Funded at Rutgers Biomedical and Health Sciences · NIH-10991356 · Data updated 2026-11-12
This study is working on creating new antiviral medicines to help kids who get sick from certain viruses that can cause respiratory issues and muscle weakness, aiming to make these treatments safer and more effective for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | December 1, 2023 |
| Project end | October 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $740,419 |
| NIH project number | 5R01AI179926-02 |
| Project ID | NIH-10991356 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 11 years old who are at risk for infections caused by non-polio enteroviruses.
✕Less likely to help
Patients who are not affected by enterovirus infections or those over the age of 11 may not receive any benefit from this research.
What this research studies
This research focuses on developing new antiviral drugs specifically targeting non-polio enteroviruses (NPEVs), which are responsible for various diseases in children, including respiratory infections and acute flaccid paralysis. The approach involves optimizing compounds that inhibit a specific protein in the virus, making them effective against multiple strains. The research will also utilize advanced techniques like X-ray crystallography to understand how these inhibitors interact with the virus at a molecular level. By improving the effectiveness and safety of these antiviral agents, the goal is to provide better treatment options for affected patients.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral medications that protect against serious enterovirus infections in children.
How similar studies have gone: While there have been efforts to develop antiviral treatments for enteroviruses, this specific approach targeting the 2C protein is novel and has not been extensively tested.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Wang, Jun — Rutgers Biomedical and Health Sciences
- Study coordinator: Wang, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.